Radiofrequency catheter ablation of persistent atrial fibrillation by pulmonary vein isolation with or without left atrial posterior wall isolation: long-term outcomes of the CAPLA trial.


Journal

European heart journal
ISSN: 1522-9645
Titre abrégé: Eur Heart J
Pays: England
ID NLM: 8006263

Informations de publication

Date de publication:
31 Aug 2024
Historique:
received: 15 07 2024
revised: 09 08 2024
accepted: 19 08 2024
medline: 1 9 2024
pubmed: 1 9 2024
entrez: 31 8 2024
Statut: aheadofprint

Résumé

Posterior wall isolation (PWI) is commonly incorporated into catheter ablation (CA) strategies for persistent atrial fibrillation (AF) in an attempt to improve outcomes. In the CAPLA randomized study, adjunctive PWI did not improve freedom from atrial arrhythmia at 12 months compared with pulmonary vein isolation (PVI) alone. Whether additional PWI reduces arrhythmia recurrence over the longer term remains unknown. In this multicenter, international, randomized study patients with persistent AF undergoing index CA using radiofrequency (RF) were randomized to PVI+PWI versus PVI alone. Patients underwent regular follow-up including rhythm monitoring for a minimum of 3 years post CA. AF burden at 3 years post-ablation was evaluated with either 28-day continuous ambulatory ECG monitoring, twice daily single-lead ECG or from cardiac implanted device. Evaluated endpoints included freedom from any documented atrial arrhythmia recurrence after a single procedure, AF burden, need for redo catheter ablation, rhythm at last clinical follow-up, healthcare utilisation metrics and AF-related quality of life. 333 of 338 (98.5%) patients (mean age 64.3±9.4 years, 23% female) completed 3-year follow-up, with 169 patients randomized to PVI+PWI and 164 patients to PVI alone. At a median of 3.62 years post-index ablation, freedom from recurrent atrial arrhythmia occurred in 59 patients (35.5%) randomized to PVI+PWI vs 68 patients (42.1%) randomized to PVI alone (HR 1.15, 95% CI 0.88-1.51, p=0.55). Median time to recurrent atrial arrhythmia was 0.53 years (IQR 0.34-1.01 years). Redo ablation was performed in 54 patients (32.0%) in the PVI+PWI group vs 49 patients (29.9%, p=0.68) in the PVI alone group. Pulmonary vein reconnection was present in 54.5% (mean number of reconnected PVs 2.2±0.9) and posterior wall reconnection in 75%. Median AF burden at 3 years was 0% in both groups (IQR 0-0.85% PVI+PWI vs 0-1.43% PVI alone, p=0.49). Sinus rhythm at final clinical follow-up was present in 85.1% with PVI+PWI vs 87.1% with PVI alone (p=0.60). Mean AF Effect On Quality-Of-Life (AFEQT) score at 3 years post-ablation was 88.0±14.8 with PVI+PWI vs 88.9±15.4 with PVI alone (p=0.63). In patients with persistent AF, the addition of PWI to PVI alone at index RF catheter ablation did not significantly improve freedom from atrial arrhythmia recurrence at long-term follow-up. Median AF burden remains low and AF quality of life high at 3 years with either ablation strategy.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
Posterior wall isolation (PWI) is commonly incorporated into catheter ablation (CA) strategies for persistent atrial fibrillation (AF) in an attempt to improve outcomes. In the CAPLA randomized study, adjunctive PWI did not improve freedom from atrial arrhythmia at 12 months compared with pulmonary vein isolation (PVI) alone. Whether additional PWI reduces arrhythmia recurrence over the longer term remains unknown.
METHODS METHODS
In this multicenter, international, randomized study patients with persistent AF undergoing index CA using radiofrequency (RF) were randomized to PVI+PWI versus PVI alone. Patients underwent regular follow-up including rhythm monitoring for a minimum of 3 years post CA. AF burden at 3 years post-ablation was evaluated with either 28-day continuous ambulatory ECG monitoring, twice daily single-lead ECG or from cardiac implanted device. Evaluated endpoints included freedom from any documented atrial arrhythmia recurrence after a single procedure, AF burden, need for redo catheter ablation, rhythm at last clinical follow-up, healthcare utilisation metrics and AF-related quality of life.
RESULTS RESULTS
333 of 338 (98.5%) patients (mean age 64.3±9.4 years, 23% female) completed 3-year follow-up, with 169 patients randomized to PVI+PWI and 164 patients to PVI alone. At a median of 3.62 years post-index ablation, freedom from recurrent atrial arrhythmia occurred in 59 patients (35.5%) randomized to PVI+PWI vs 68 patients (42.1%) randomized to PVI alone (HR 1.15, 95% CI 0.88-1.51, p=0.55). Median time to recurrent atrial arrhythmia was 0.53 years (IQR 0.34-1.01 years). Redo ablation was performed in 54 patients (32.0%) in the PVI+PWI group vs 49 patients (29.9%, p=0.68) in the PVI alone group. Pulmonary vein reconnection was present in 54.5% (mean number of reconnected PVs 2.2±0.9) and posterior wall reconnection in 75%. Median AF burden at 3 years was 0% in both groups (IQR 0-0.85% PVI+PWI vs 0-1.43% PVI alone, p=0.49). Sinus rhythm at final clinical follow-up was present in 85.1% with PVI+PWI vs 87.1% with PVI alone (p=0.60). Mean AF Effect On Quality-Of-Life (AFEQT) score at 3 years post-ablation was 88.0±14.8 with PVI+PWI vs 88.9±15.4 with PVI alone (p=0.63).
CONCLUSIONS CONCLUSIONS
In patients with persistent AF, the addition of PWI to PVI alone at index RF catheter ablation did not significantly improve freedom from atrial arrhythmia recurrence at long-term follow-up. Median AF burden remains low and AF quality of life high at 3 years with either ablation strategy.

Identifiants

pubmed: 39215996
pii: 7742127
doi: 10.1093/eurheartj/ehae580
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

Auteurs

J William (J)

The Alfred Hospital, Melbourne, Australia.
Monash University, Melbourne, Australia.
The Baker Heart and Diabetes Research Institute, Melbourne, Australia.

D Chieng (D)

The Alfred Hospital, Melbourne, Australia.
The Baker Heart and Diabetes Research Institute, Melbourne, Australia.
University of Melbourne, Melbourne, Australia.

A G Curtin (AG)

Baker Heart Research Institute and the Alfred Hospital Melbourne.

H Sugumar (H)

The Alfred Hospital, Melbourne, Australia.
Monash University, Melbourne, Australia.
Cabrini Health, Melbourne, Australia.
St Vincent's Hospital, Melbourne, Australia.

L H Ling (LH)

The Alfred Hospital, Melbourne, Australia.
The Baker Heart and Diabetes Research Institute, Melbourne, Australia.
University of Melbourne, Melbourne, Australia.

L Segan (L)

The Alfred Hospital, Melbourne, Australia.
The Baker Heart and Diabetes Research Institute, Melbourne, Australia.
University of Melbourne, Melbourne, Australia.

R Crowley (R)

The Alfred Hospital, Melbourne, Australia.
The Baker Heart and Diabetes Research Institute, Melbourne, Australia.
University of Melbourne, Melbourne, Australia.

Anoushka Iyer (A)

Monash University, Melbourne, Australia.

S Prabhu (S)

The Alfred Hospital, Melbourne, Australia.
The Baker Heart and Diabetes Research Institute, Melbourne, Australia.
University of Melbourne, Melbourne, Australia.

A Voskoboinik (A)

The Alfred Hospital, Melbourne, Australia.
Monash University, Melbourne, Australia.
The Baker Heart and Diabetes Research Institute, Melbourne, Australia.
University of Melbourne, Melbourne, Australia.
Cabrini Health, Melbourne, Australia.

J B Morton (JB)

University of Melbourne, Melbourne, Australia.
Royal Melbourne Hospital, Melbourne, Australia.

G Lee (G)

University of Melbourne, Melbourne, Australia.
Royal Melbourne Hospital, Melbourne, Australia.

A J McLellan (AJ)

University of Melbourne, Melbourne, Australia.
St Vincent's Hospital, Melbourne, Australia.
Royal Melbourne Hospital, Melbourne, Australia.

R K Pathak (RK)

Canberra Heart Rhythm, Australian National University, ACT, Australia.

L Sterns (L)

Royal Jubilee Hospital, Vancouver Island, British Columbia, Canada.

M Ginks (M)

John Radcliffe Hospital, Oxford, UK.

C M Reid (CM)

Curtin University, Perth, Australia.

P Sanders (P)

Royal Adelaide Hospital, Adelaide, Australia.

J M Kalman (JM)

Monash University, Melbourne, Australia.
University of Melbourne, Melbourne, Australia.
Royal Melbourne Hospital, Melbourne, Australia.

P M Kistler (PM)

The Alfred Hospital, Melbourne, Australia.
Monash University, Melbourne, Australia.
The Baker Heart and Diabetes Research Institute, Melbourne, Australia.
University of Melbourne, Melbourne, Australia.
Cabrini Health, Melbourne, Australia.

Classifications MeSH